SBIR/STTR Research Award

Transgenic plant cells as source of hepatoprotective dr*

Award identifier 37fad73ea382081dc47f0dbc8bd9082f9e78f64dcb49aba5d53767ef8e57d152Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$100,000

Program and phase

STTR · Phase I

Award year

2003

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
NAPROGENIX, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
N1NBJ43SQGX7
Solicitation number
Not reported
Topic code
Not reported

Research abstract

Transgenic plant cells as source of hepatoprotective drugs. Alcoholic liver damage (ALD) is among the ten most common causes of death in the USA. The liver may be uniquely sensitive because it metabolizes ethanol at a high rate. This generates acetaldehyde intracellularly, damaging cell components directly, and/or inducing apoptotic cell death. Although some plant natural products are protective it would be of value to discover agents with greater efficacy against ALD. Here, a novel biotechnology, based on selection of mutant plant cells for resistance to alcohol, followed by high throughput pharmacological screening (HTPS) of extracts from surviving cells, is applied to this problem. The mutant population will be generated by activation tagging mutagensis, and extracts from the resulting alcohol-resistant clonal cultures screened for protection of hepatocyte cultures against ethanol-induced damage. However, because plant cells in culture metabolize ethanol to a very limited extent, we propose first to produce transgenic plant lines (N tabacum) over-expressing the activated gene for plant or mammalian ADH. Cell cultures derived from these plants will be evaluated for similarities to mammalian liver cells in metabolism of ethanol to acetaldehyde. Phase 1 is the creation of these ADH-expressing (ADHE) lines. In subsequent phases, hepatoprotective compounds from resitant clonal extracts will be tentatively identified by GC/MS. Regardless of whether novel compounds are discovered, the ADHE plant lines, and the ethanol resistant clonal cultures are patentable and represent a valuable resource for development of alcohol-related medications in the future.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

21 SBIR/STTR records share this UEI (2003–2021). Reported award amounts total $17,103,921. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.